Condition 1: Chronic Viral Hepatitis-C. Condition 2: Chronic kidney disease, stage 5. Chronic viral hepatitis C Chronic kidney disease, stage 5
Conditions
Interventions
Intervention 1: Intervention group 1: Daclatasvir 60 mg + Sofosbuvir 400 mg once daily for 12 weeks. Intervention 2: Intervention group 2: Daclatasvir 60 mg per day and Sofosbuvir 400 mg 3 times / per
Sponsors
Jinnah Hospital, Lahore
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Male & Female (non-pregnant) being at the age of 18 years and over End stage renal disease patients undergoing maintenance hemodialysis detected with HCV RNA by PCR.
Exclusion criteria
Exclusion criteria: Patients having co-infection with HBV, HIV. Patients with decompensated cirrhosis and terminal illness. Patients hypersensitive to any of the ingredients of treatment drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained Virologic Response (SVR) assessed. Timepoint: 24th week after start of treatment. Method of measurement: HCV RNA- PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| End of Treatment response (ETR). Timepoint: 12th week of start of treatment. Method of measurement: HCV RNA-PCR. | — |
Countries
Pakistan
Contacts
Public ContactProf. Dr. Shafiq Ur Rehman Cheema
Jinnah Hospital & Allama Iqbal Medical College, Lahore
Outcome results
None listed